Isoniazid, an anti-tuberculosis drug. It is commercially available as an oral tablet and as an injection for intramuscular, intravenous, or IV administration; isoniazid spray is not yet available.
Isoniazid is usually used in combination with other anti-tuberculosis drugs for the treatment of all types of tuberculosis, including tuberculous meningitis, as well as other mycobacterial infections.
Adverse effects include unsteady gait, numbness of the extremities, finger pain, dark urine, yellowing of the scleral skin, poor appetite, malaise, and vomiting; blurred vision, eye pain, fever, rash, and gynecomastia may also occur.
Note that it is contraindicated in patients who are allergic to isoniazid and its constituents; it is contraindicated in patients with abnormal liver function, psychiatric patients and epileptic patients. Liver function should be checked regularly for abnormalities before and during the course of treatment, and attention should be paid to the presence or absence of prodromal symptoms of hepatitis; the drug should be stopped immediately when symptoms of hepatotoxicity such as pain in the liver area, nausea, vomiting and signs such as yellowing of the skin and mucous membranes, ascites, etc. are present.
It is recommended that isoniazid be taken in strict compliance with medical advice, avoiding self-medication and adjustment of drug dosage, to avoid the occurrence of adverse effects.